Andrew Witty - UnitedHealth Group CEO
| UNH Stock | USD 608.38 1.59 0.26% |
CEO
Mr. Andrew Philip Witty is re designated as Chief Executive Officer of Optum, Executive Vice President, Director of the Company, effective July 1, 2018. Sir Andrew Witty was CEO and a board member of GlaxoSmithKline plc, a global pharmaceutical company, from 2008 to April, 2017. He joined GSK in 1985 and, prior to 2008, served in various senior roles in Europe, South Africa, the U.S. and Asia. Witty is Chancellor of the University of Nottingham, a British public research university, and has served in that capacity since January 2013. He is a Business Ambassador for the U.K. Prime Minister. Witty serves on the Singapore Economic Development Board International Advisory Committee, the Council at the London School of Hygiene and Tropical Medicine, and as an Advisor to the Bill and Melinda Gates Foundation. Witty was knighted in the 2012 New Year Honours for services to the economy and the U.K. pharmaceutical industry. He also serves on the board of G1 Therapeutics, Inc. since 2021.
| Age | 55 |
| Tenure | 3 years |
| Professional Marks | MBA |
| Address | UnitedHealth Group Center, Minnetonka, MN, United States, 55343 |
| Phone | 952 936 1300 |
| Web | https://www.unitedhealthgroup.com |
Andrew Witty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Witty against UnitedHealth Group stock is an integral part of due diligence when investing in UnitedHealth Group. Andrew Witty insider activity provides valuable insight into whether UnitedHealth Group is net buyers or sellers over its current business cycle. Note, UnitedHealth Group insiders must abide by specific rules, including filing SEC forms every time they buy or sell UnitedHealth Group'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Witty over a year ago Payment of 372 shares by Andrew Witty of UnitedHealth Group subject to Rule 16b-3 | ||
Andrew Witty over a year ago Acquisition by Andrew Witty of 100 shares of UnitedHealth Group subject to Rule 16b-3 |
UnitedHealth Group Management Efficiency
The company has Return on Asset of 0.0692 % which means that on every $100 spent on assets, it made $0.0692 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1525 %, implying that it generated $0.1525 on every 100 dollars invested. UnitedHealth Group's management efficiency ratios could be used to measure how well UnitedHealth Group manages its routine affairs as well as how well it operates its assets and liabilities. As of now, UnitedHealth Group's Return On Capital Employed is increasing as compared to previous years. The UnitedHealth Group's current Return On Equity is estimated to increase to 0.26, while Return On Tangible Assets are projected to decrease to 0.09. As of now, UnitedHealth Group's Total Current Assets are increasing as compared to previous years. The UnitedHealth Group's current Intangible Assets is estimated to increase to about 16 B, while Other Current Assets are projected to decrease to under 6.2 B.Similar Executives
| Found 7 records | CEO Age | ||
| Karen Lynch | CVS Health Corp | 61 | |
| David Cordani | Cigna Corp | 59 | |
| Gail Boudreaux | Elevance Health | 63 | |
| Rich Fisher | Centene Corp | N/A | |
| Timothy Wentworth | Cigna Corp | 59 | |
| Joseph Zubretsky | Molina Healthcare | 67 | |
| Larry Merlo | CVS Health Corp | 63 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0692 |
UnitedHealth Group Leadership Team
Elected by the shareholders, the UnitedHealth Group's board of directors comprises two types of representatives: UnitedHealth Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UnitedHealth. The board's role is to monitor UnitedHealth Group's management team and ensure that shareholders' interests are well served. UnitedHealth Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UnitedHealth Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Wilensky, Independent Director | ||
| Richard Burke, Independent Chairman of the Board | ||
| Brian CPA, Chief UnitedHealthcare | ||
| Valerie Rice, Independent Director | ||
| Andrew Witty, Group President, Chief Executive Officer, Executive Vice President, Director | ||
| Terry Clark, Executive Officer | ||
| Sir Witty, CEO Director | ||
| Stephen Hemsley, Non-Executive Chairman of the Board | ||
| John Rex, Chief Financial Officer, Executive Vice President | ||
| Dirk McMahon, President and Chief Operating Officer; Chief Executive Officer of UnitedHealthcare | ||
| Zachary Sopcak, Senior Relations | ||
| Chris Zaetta, Chief VP | ||
| John Noseworthy, Independent Director | ||
| Jennifer Smoter, Senior Officer | ||
| William Ballard, Independent Director | ||
| Glenn Renwick, Independent Director | ||
| Rupert Bondy, Compliance Governance | ||
| Sandeep Dadlani, Executive Officer | ||
| Michele Hooper, Lead Independent Director | ||
| Timothy Flynn, Independent Director | ||
| Thomas Roos, Senior Vice President, Chief Accounting Officer | ||
| Matthew Friedrich, Executive Vice President Chief Legal Officer | ||
| D Wilson, Executive Vice President - Human Capital | ||
| F McNabb, Independent Director | ||
| Paul Garcia, Independent Director | ||
| Marianne Short, Executive Vice President, Chief Legal Officer | ||
| David Wichmann, Chief Executive Officer, Director | ||
| Patricia Lewis, Chief Human Resource Officer, Executive Vice President | ||
| Brian Thompson, Executive UnitedHealthcare | ||
| James Barry, Director Pennsylvania |
UnitedHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UnitedHealth Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0692 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 599.3 B | ||||
| Shares Outstanding | 920.28 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 90.10 % | ||||
| Number Of Shares Shorted | 8.14 M | ||||
| Price To Earning | 26.34 X |
Currently Active Assets on Macroaxis
When determining whether UnitedHealth Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UnitedHealth Group's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Unitedhealth Group Incorporated Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Unitedhealth Group Incorporated Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UnitedHealth Group Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UnitedHealth Group. If investors know UnitedHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UnitedHealth Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.043 | Dividend Share 7.96 | Earnings Share 15.35 | Revenue Per Share 427.221 | Quarterly Revenue Growth 0.092 |
The market value of UnitedHealth Group is measured differently than its book value, which is the value of UnitedHealth that is recorded on the company's balance sheet. Investors also form their own opinion of UnitedHealth Group's value that differs from its market value or its book value, called intrinsic value, which is UnitedHealth Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UnitedHealth Group's market value can be influenced by many factors that don't directly affect UnitedHealth Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UnitedHealth Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if UnitedHealth Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UnitedHealth Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.